Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024Business Wire • 09/09/24
Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk PatientsBusiness Wire • 09/04/24
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024Business Wire • 08/29/24
Aditxt's Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)Business Wire • 08/26/24
Aditxt Announces Third Amendment to Arrangement Agreement with Appili TherapeuticsBusiness Wire • 08/21/24
Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral SolutionPRNewsWire • 08/20/24
Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders' Meeting, Setting the Stage for 2024 and 2025 Strategic PlansBusiness Wire • 08/13/24
Aditxt Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesBusiness Wire • 08/09/24
Aditxt Announces $1.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesBusiness Wire • 08/09/24
Aditxt Subsidiary Pearsanta Seeks Clinical Trial Translational Endpoints Research Award for Early Detection of Ovarian CancerBusiness Wire • 08/07/24
Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1stGlobeNewsWire • 07/25/24
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the AcquisitionBusiness Wire • 07/25/24
Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 ClosingBusiness Wire • 07/17/24
Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSECPRNewsWire • 07/15/24
Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's HealthcarePRNewsWire • 06/27/24
Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of MatterPRNewsWire • 06/11/24
CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq RulesBusiness Wire • 05/03/24
Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq RulesBusiness Wire • 05/03/24
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)Business Wire • 04/02/24